Key Events This Week
15 Jun: Bullish momentum confirmed with 2.64% gain to Rs.229.30
17 Jun: Valuation shift to "very expensive" category noted at Rs.239.40
18 Jun: New 52-week high reached at Rs.252.95
19 Jun: Week closes at Rs.237.70, down 1.80% on the day

Sun Pharma Advanced Research Company Ltd is Rated Buy
2026-06-19 10:10:57Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 19 June 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Broad-Based Technical Strength Lifts Sun Pharma Advanced Research Company Ltd to 52-Week High of Rs 252.95
2026-06-18 14:10:18With a decisive break above Rs 252.95 on 18 Jun 2026, Sun Pharma Advanced Research Company Ltd has reached a new 52-week high, marking a significant milestone in its ongoing price momentum. This surge comes after a sustained five-day rally that has propelled the stock up by over 21% in that period, outpacing its sector by 3.05% on the day.
Read full news article
Sun Pharma Advanced Research Company Ltd: Valuation Shift Signals Price Attractiveness Change
2026-06-17 08:00:56Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its valuation parameters, moving from an 'expensive' to a 'very expensive' rating. This change, driven by key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a significant alteration in the stock's price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.
Read full news article
Sun Pharma Advanced Research Company Ltd Sees Bullish Momentum Amid Technical Parameter Shift
2026-06-15 08:03:38Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in price momentum, with technical indicators signalling a transition from mildly bullish to bullish trends. The stock’s recent surge, coupled with upgraded technical grades and a strong Mojo Score, underscores renewed investor interest in this small-cap pharmaceutical player amid a volatile market backdrop.
Read full news articleSun Pharma Advanced Research Company Ltd Gains 0.26%: 4 Key Factors Driving the Week
2026-06-13 17:13:20
Key Events This Week
1 June: Intraday low amid price pressure (Rs.196.40)
1 June: Outstanding Q4 2026 financial results announced
2 June: Quality grade downgraded from 'Good' to 'Average'
4 June: Mixed technical signals amid price momentum shift
5 June: Week closes at Rs.212.45 (+0.26%) outperforming Sensex

Sun Pharma Advanced Research Company Ltd Surges 7.4% to Day's High of Rs 221.75 — Outperforms Sector by 6.34 Percentage Points
2026-06-12 11:46:39The Sensex gained 1.13% on 12 Jun 2026, but Sun Pharma Advanced Research Company Ltd (SPARC) outpaced the broader market with a robust 7.4% rally, touching an intraday high of Rs 221.75. This 6.34 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector signals a distinctly stock-specific momentum shift rather than a mere market tailwind.
Read full news article
Sun Pharma Advanced Research Company Ltd is Rated Buy
2026-06-08 10:10:40Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was adjusted on that date, the analysis below reflects the stock's current fundamentals, returns, and financial metrics as of 08 June 2026, providing investors with an up-to-date perspective on the company’s standing.
Read full news article
Sun Pharma Advanced Research Company Ltd is Rated Buy
2026-06-07 10:10:33Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 June 2026, providing investors with the most up-to-date insight into its performance and outlook.
Read full news article





